Tabula Rasa HealthCare Inc (NASDAQ:TRHC)’s share price traded down 6.1% during mid-day trading on Thursday following insider selling activity. The company traded as low as $31.64 and last traded at $32.25. 582,097 shares were traded during mid-day trading, an increase of 133% from the average session volume of 249,872 shares. The stock had previously closed at $34.33.
Specifically, major shareholder Growth Fund 1Q Lp Originate sold 684,180 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $25.85, for a total value of $17,686,053.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian W. Adams purchased 5,391 shares of the business’s stock in a transaction on Friday, January 12th. The stock was purchased at an average cost of $14.23 per share, with a total value of $76,713.93. The disclosure for this purchase can be found here. Insiders have sold a total of 1,359,422 shares of company stock valued at $37,411,141 in the last three months. 45.80% of the stock is owned by insiders.
Several equities analysts have commented on TRHC shares. BidaskClub raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Citigroup started coverage on Tabula Rasa HealthCare in a report on Thursday, January 4th. They issued a “buy” rating for the company. Zacks Investment Research cut Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. Oppenheimer started coverage on Tabula Rasa HealthCare in a report on Monday, December 18th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, William Blair started coverage on Tabula Rasa HealthCare in a report on Monday, December 11th. They issued an “outperform” rating for the company. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $29.78.
The firm has a market cap of $612.76, a P/E ratio of -129.92, a price-to-earnings-growth ratio of 3.58 and a beta of 3.93. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73.
Several hedge funds have recently added to or reduced their stakes in TRHC. Ranger Investment Management L.P. grew its stake in shares of Tabula Rasa HealthCare by 896.7% in the 4th quarter. Ranger Investment Management L.P. now owns 777,341 shares of the company’s stock valued at $21,804,000 after purchasing an additional 699,352 shares during the period. UBS Asset Management Americas Inc. bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at approximately $9,559,000. Peregrine Capital Management LLC bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at approximately $9,122,000. Castleark Management LLC bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at approximately $6,393,000. Finally, Pier Capital LLC bought a new stake in shares of Tabula Rasa HealthCare in the 3rd quarter valued at approximately $4,151,000. Institutional investors own 41.58% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/24/tabula-rasa-healthcare-trhc-trading-down-6-1-on-insider-selling.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.